Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTAL long-term extension study of the Port Delivery System with ranibizumab in neovascular age-related macular degeneration
2023-507131-38-00Phase 3Authorised
- Sponsor
- Roche
- Start
- May 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in exudative macular degeneration, sponsored by Roche. Primary endpoints: Incidence and severity of ocular and systemic adverse events, Adverse events of special interest and 3 more. Planned start May 2022; status: authorised.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2023-507131-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507131-38-00.